Wall Street analyst estimates for Enanta Pharmaceuticals, Inc. (ENTA): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV).
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-16 | $-0.77 | ||
| 2026-08-10 | $-0.67 | $-0.51 | -31.5% |
| 2026-05-11 | $-0.45 | $-0.46 | +2.2% |
| 2026-02-09 | $-0.42 | $-0.54 | +22.2% |
| 2025-11-17 | $-0.87 | $-1.13 | +23.0% |
| 2025-08-11 | $-0.85 | $-1.25 | +32.0% |
| 2025-05-12 | $-1.06 | $-1.04 | -1.9% |
| 2025-02-10 | $-1.05 | $-1.16 | +9.5% |
Valuation Ratios
| Price / Book | 3.65 |
| EV / EBITDA | -8.58 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $88.3M | $102.8M | $206.6M | $205.2M | $122.5M | $97.1M | $86.2M | $79.2M | $67.6M | $65.3M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $4.6M |
| Gross Profit | $88.3M | $102.8M | $206.6M | $205.2M | $122.5M | $97.1M | $86.2M | $79.2M | $67.6M | $60.7M |
| Research & Development | $40.5M | $57.5M | $94.9M | $142.2M | $136.8M | $174.1M | $164.5M | $163.5M | $131.5M | $106.7M |
| Selling, General & Admin | $17.0M | $20.7M | $23.4M | $26.2M | $27.4M | $32.5M | $45.5M | $52.9M | $57.9M | $43.9M |
| Operating Expenses | $57.4M | $78.2M | $118.3M | $168.5M | $164.1M | $206.6M | $210.0M | $216.4M | $189.3M | $146.1M |
| Operating Income | $30.8M | $24.6M | $88.3M | $36.7M | -$41.6M | -$109.6M | -$123.8M | -$137.2M | -$121.7M | -$85.3M |
| EBITDA | $32.5M | $26.8M | $90.8M | $40.0M | -$38.0M | -$104.2M | -$119.2M | -$123.5M | -$104.5M | -$70.8M |
| Interest Expense | $45000 | $40000 | $4.9M | 0 | 0 | 0 | 0 | $5.1M | $10.9M | $7.7M |
| Pre-tax Income | $32.6M | $26.9M | $93.1M | $45.6M | -$35.0M | -$107.6M | -$122.2M | -$131.0M | -$117.8M | -$83.5M |
| Income Tax | $10.9M | $9.2M | $21.2M | -$826000 | $1.1M | -$28.6M | -$433000 | $2.8M | -$1.7M | -$1.7M |
| Net Income | $21.7M | $17.7M | $72.0M | $46.4M | -$36.2M | -$79.0M | -$121.8M | -$133.8M | -$116.0M | -$81.9M |
| EPS | $1.14 | $0.93 | $3.48 | $2.37 | $-1.81 | $-3.92 | $-5.91 | $-6.38 | $-5.48 | $-3.84 |
| EPS (Diluted) | $1.13 | $0.91 | $3.48 | $2.21 | $-1.81 | $-3.92 | $-5.91 | $-6.38 | $-5.48 | $-3.84 |
| Shares Outstanding (Diluted) | $19.2M | $19.4M | $20.6M | $21.0M | $19.9M | $20.2M | $20.6M | $21.0M | $21.2M | $21.3M |
Price
| Price | $12.70 |
| Market Cap | $369M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ASMB · AVIR · CRBU · FHTX · IMRX · NAUT · PRLD
Explore sector: Healthcare · Biotechnology
More sections of ENTA: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks